The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.
 
Beverly Moy
Consulting or Advisory Role - MOTUS (I)
Research Funding - Puma Biotechnology (Inst)
 
Masato Takahashi
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly; Nippon Kayaku; Pfizer
Research Funding - Eisai (Inst); Kyowa Hakko Kirin (Inst); Nippon Kayaku (Inst); Taiho Pharmaceutical (Inst)
 
Shoichiro Ohtani
No Relationships to Disclose
 
Ewa Chmielowska
No Relationships to Disclose
 
Naohito Yamamoto
No Relationships to Disclose
 
Bruno P. Coudert
Honoraria - AstraZeneca; Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Roche
 
Feng Xu
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Alvin F. Wong
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Arlene Chan
Honoraria - Lilly; Novartis
Consulting or Advisory Role - Lilly
Research Funding - Eisai